State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression

Current Opinion in Organ Transplantation

Volumn 15, Issue 6, 2010, Pages 691-696

  Sawitzki, Birgit ^a,b   Reinke, Petra ^b   Pascher, Andreas ^c   Volk, Hans Dieter ^a,b  

^a CCM   (Germany)

^b CVK   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

B cell; Elispot; gene marker; human leukocyte antigen antibodies; plasma cell; transplantation

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CD19 ANTIBODY; CD20 ANTIBODY; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD44V ANTIGEN; CD79B ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; HLA ANTIBODY; IMMUNOGLOBULIN D; TRANSCRIPTION FACTOR FOXP3; VIMENTIN;

ANTIBODY RESPONSE; B LYMPHOCYTE; BIOPSY; CELL INFILTRATION; CELL POPULATION; CHRONIC GRAFT REJECTION; CLINICAL ASSESSMENT; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLOW UP; GRAFT RECIPIENT; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT; MAINTENANCE THERAPY; MARKER GENE; MEDICAL RESEARCH; MEMORY CELL; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; OPERATIONAL TOLERANT RENAL TRANSPLANT RECIPIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; RNA PURIFICATION; SCREENING; TREATMENT WITHDRAWAL;

B-LYMPHOCYTES; BIOLOGICAL MARKERS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; WITHHOLDING TREATMENT;

EID: 78649637231     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834066b0     Document Type: Review

References (45)

1. Nickerson P. Posttransplant monitoring of renal allografts: are we there yet? Curr Opin Immunol 2009; 21:563-568.
2. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120:1836-1847.
3. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120:1848-1861.
4. +Tcells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplan-tation 2006; 81:398-407.
5. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78:503-513.
6. Zhao G, Moore DJ, Lee KM, et al. An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Am J Transplant 2010; 10:796-801.
7. Deng S, Moore DJ, Huang X, et al. Cutting edge:transplanttolerance induced byanti-CD45RB requires B lymphocytes. J Immunol 2007; 178:6028-6032.
8. Liu Y, Li L, Kumar KR, et al. Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J Immunol 2007; 179:1340-1352.
9. Vela JL, Ait-Azzouzene D, Duong BH, et al. Rearrangement of mouse immunoglobulin kappa deleting element recombining sequence promotes immune tolerance and lambda B cell production. Immunity 2008; 28:161-170.
10. Reichardt P, Dornbach B, Rong S, et al. Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007; 110:1519-1529.
11. Burns AM, Ma L, Li Y, et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J Immunol 2009; 182:1314-1324.
12. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104:15448-15453.
13. Sawitzki B, Schlickeiser S, Reinke P, et al. Pretransplant immune risk assessment. Curr Opin Organ Transplant 2009; 14:650-655.
14. Sawitzki B, Bushell A, Steger U, et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 2007; 7:1091-1102.
15. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Usingtranscriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118:2845-2857.
16. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7:309-319.
17. Benitez C, Lozano JJ, Fueyo AS. Gene expression profiling and transplanta-tion tolerance in the clinic. Transplantation 2009; 88:S50-S53.
18. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation.Transplantation 2009; 87:606-614.
19. Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009; 88:421-428.
20. Grinyo JM, Cruzado JM. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress. Am J Transplant 2009; 9:2447-2452.
21. Demetris AJ, Lunz JG 3rd, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22:120-141.
22. Goldman M, Wood K. Translating transplantation tolerance in the clinic: where are we, where do we go? Clin Exp Immunol 2009; 156:185-188.
23. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
24. Rush D. Can protocol biopsy better inform our choices in renal transplanta-tion? Transplant Proc 2009; 41:S6-S8.
25. Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7:356-365.
26. Kers J, Xu-Dubois YC, Rondeau E, et al. Intragraft tubularvimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy. Transplantation 2010; 90:502-509.
27. +T cells within renal allografts shows infiltration oftubules mimicking rejection. Am J Pathol 2007; 171:1915-1922.
28. +cells in renal allograftsduring acuterejection. Am JTransplant 2007; 7:914-922.
29. Yapici U, Bemelman FJ, Scheepstra CG, et al. Intragraft FOXP3 protein or mRNA during acute renal allograft rejection correlates with inflammation, fibrosis, and poor renal outcome. Transplantation 2009; 87:1377-1380.
30. Porcheray F, Wong W, Saidman SL, et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant 2009; 9:2126-2135.
31. Bloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9:1835-1845.
32. Lachmann N, Terasaki PI, Budde K, et al. Antihuman leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87:1505-1513.
33. Keeren K, Friedrich M, Gebuhr I, et al. Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol 2009; 183:4077-4087.
34. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344:947-954.
35. Kotsch K, Mashreghi MF, Bold G, et al. Enhanced granulysin mRNA expres-sion in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 2004; 77:1866-1875.
36. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353:2342-2351.
37. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010; 90:394-400.
38. Seiler M, Brabcova I, Viklicky O, et al. Heightened expression of the cyto-toxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation. Am J Transplant 2007; 7:423-433.
39. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65:2390-2397.
40. Matz M, Beyer J, Wunsch D, et al. Early posttransplant urinary IP-10 expres-sion after kidney transplantation is predictive of short-and long-term graft function. Kidney Int 2006; 69:1683-1690.
41. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9:1347-1353.
42. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009; 87:1814-1820.
43. Quintana LF, Campistol JM, Alcolea MP, et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics 2009; 8:1658-1673.
44. Quintana LF, Sole-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronicallograftdys function. J Am Soc Nephrol 2009; 20:428-435.
45. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol 2010; 21:646-653.